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ABSTRACT 
 
EFFECTS OF HEMOGLOBIN-BASED OXYGEN CARRIERS ON VASOACTIVITY 
IN THE SPINOTRAPEZIUS MUSCLE OF THE RAT 
 
By Pete Dennis Meliagros 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2008 
 
Advisor: Roland N. Pittman, Ph.D. 
    Department of Physiology and Biophysics 
 
 
Hemoglobin-based oxygen carriers (HBOCs) offer a safe, more plentiful and long term 
alternate to blood banks.  However, they have been found to increase blood pressure 
which can be attributed to an increase in total peripheral resistance (TPR).  Lumenal 
nitric oxide (NO) scavenging by these HBOCs seems to be responsible for this 
hypertensive effect.  In addition, it is believed that hemoglobin (Hb) tetramers and dimers 
may extravasate and consume additional nitric oxide in the perivascular and interstitial 
space.  The purpose of the present study was to elucidate the role of NO scavenging and 
to confirm extravasation as a contributor to HBOC vasopressor effects in the 
spinotrapezius muscle.  The present study investigated the vessel reactivity and mean 
arterial pressure response to three HBOCs: HBOC 201, HBOC 205 MW 400, and HBOC 
205 MW 600.  These varied in molecular weight (MW) and percentage of tetramers and 
dimers.  It was found that larger polymers of HBOC showed no significant decrease in 
vasoactivity.  Although larger polymers are less likely to extravasate, the remaining 
tetramers and dimers seem sufficient to contribute to the observed vasoactivity.  Using 
NaNO2, a NO donor, in conjunction with the HBOCs almost completely abolished this 
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hypertensive effect at higher concentrations.  Further examination utilizing a nitric oxide 
synthase (NOS) inhibitor to mimic the HBOC vasopressor effects demonstrated that 
lower concentrations of NaNO2 were able to abolish the hypertensive effect.  In vitro 
studies only further supported these results by demonstrating that NO consumption 
increases with HBOC dose.  HBOC labeled with TRITC showed conclusive evidence 
that extravasation also plays a role in NO scavenging, even when minimal amounts of 
tetramers and dimers are present.  In conclusion, the present study offers strong evidence 
that NO scavenging is responsible for the observed vasopressor effects.  It also offers 
evidence supporting the theory that HBOC extravasation may be contributing to these 
vasopressor effects as well. 
 
 
 
 1
INTRODUCTION 
The cardiovascular system is responsible for maintaining several homeostatic 
functions.  In addition to being a component of arterial blood pressure and body 
temperature, it also delivers regulatory hormones and oxygen throughout the body.  The 
cardiovascular system consists of a branching system of blood vessels that allow 
adjustments to altered physiologic states such as hemorrhage and exercise. 
 Blood is the medium of the cardiovascular system that carries these homeostatic 
factors in blood vessels throughout the body.  Blood consists of four components: 
plasma, erythrocytes, leukocytes, and thrombocytes.  Blood consists of approximately 55 
% plasma by volume, which functions to suspend the erythrocytes and leukocytes.  The 
erythrocytes, or red blood cells (RBC), consist of approximately 40-45 % of the blood 
volume and function to carry oxygen and nutrients to tissues and carbon dioxide and 
waste products away from tissues.  The leukocytes, or white blood cells, consist of less 
than 0.1% of the blood volume and play a role in the immune system.  Thrombocytes, or 
platelets, consist of less than 0.1 % of the blood volume and are involved in blood 
clotting. 
Oxygen delivery to tissues is important because it enables cells to produce energy 
more efficiently by means of oxidative phosphorylation.  Oxygen transport 
predominately occurs in the microcirculation.  The microcirculation begins with the 
arterioles which have a thin sleeve of smooth muscle to regulate blood flow.  The 
arterioles give rise to multiple capillaries that have thin walls which allow simple 
diffusion of small solutes and gases.  The capillaries then converge into venules.  The 
increase in oxygen consumption in the microcirculation, predominantly in the capillaries, 
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is due to the lower velocity of blood and the larger surface area-to-volume ratio found in 
these smaller vessels. 
In pathological states that exhibit hemorrhage, the traditional treatments involve 
resuscitation with colloid or crystalloid solutions.  Although these solutions are effective 
and highly available, they are not ideal for resuscitation.  These solutions replenish the 
blood volume and therefore increase cardiac output, but are not sufficient to oxygenate 
tissues under severe blood loss.  Extended use of these solutions may result in severe 
tissue decay.  Blood is currently the ideal resuscitation fluid, but it has many 
disadvantages.  These include the cost of acquiring and screening the blood, its short 
storage life of 42 days, and the possibility of transmitting diseases.  Perfluorocarbons 
(PFCs) and hemoglobin-based oxygen carriers (HBOCs) are two types of blood 
substitutes that are currently being tested as possible alternative means of resuscitation.  
PFCs are synthetic molecules in which a linear or cyclic carbon backbone is substituted 
with fluorine.  PFCs are emulsified in a particular solution (58 % perfluoroctyl bromide 
and 2% perfluorodecyl bromide) that improves its flow in the circulation.  PFCs deliver 
oxygen and carbon dioxide; however, they exhibit a linear relationship between oxygen 
carrying capacity and partial pressure of oxygen.  Therefore, they require high inspiratory 
oxygen concentrations to deliver sufficient oxygen to tissues.  The present study focuses 
on the use of hemoglobin-based oxygen carrier as blood substitutes. 
HBOC Background 
With the limited blood supply and concerns regarding disease transmission, as 
well as transfusion reactions, there has been much progress investigating the use of 
HBOCs.  These solutions offer universal compatibility, freedom of disease transmission, 
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and long storage life.  HBOCs are derived from modified human or animal hemoglobin 
and from recombinant human hemoglobin (Pawson et al., 2007).  Regardless of its 
efficacy and potential, certain undesirable side effects impede HBOC use clinically.  
HBOCs are known to increase mean arterial pressure (MAP) due to systemic 
vasoconstriction, cause some gastrointestinal discomfort and loss of motility, and induce 
kidney failure. Hypertension and gastrointestinal discomfort are assuredly due to the 
influence of HBOCs on smooth muscle tone.  Kidney damage is caused by tetramer 
dissociation into dimers which cause oxidative stress (Chang et al., 2001). Structural 
modifications have been devised to reduce these effects and to prolong HBOC half-life.   
These modifications include covalent intramolecular links, cross-linked hemoglobin (Hb) 
linked with polyalkylene oxides, covalently linked macromolecules (such as dextran) to 
Hb, polymerization of Hb tetramers, or microencapsulated Hb solutions.  Currently, 
HBOC use has yet to be approved clinically in humans because vasoconstriction and 
hypertension are severe side effects that persist. 
Theories of HBOC Side Effects 
 There are two competing theories that purport to account for the observed 
vasoconstriction and vasopressor effects.  One theory attributes the systemic 
vasoconstriction to changes in concentration of vasoactive molecules such as endothelins 
and NO.  The second theory suggests that vasoconstriction is due to an overcompensating 
autoregulatory response to excessive O2 delivery caused by the more efficient 
extracellular Hb molecules (Winslow, 2000). 
 An advantage of HBOCs is their ability to transport oxygen efficiently to tissues.  
Some believe that the low oxygen affinity of many HBOCs may in fact increase the 
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oxygen levels in regulatory arterioles and therefore induce an autoregulatory response in 
which vasoconstriction increases vascular resistance and reduces flow (Winslow, 2000).  
There has been much debate in the literature over this theory.  Rolhf et al (Rolhf et al., 
1998) conducted studies comparing cross-linked Hb tetramers that differed in oxygen 
affinity and cooperativity.  They deduced a direct inverse correlation between oxygen 
affinity and vasopressor response.  HBOCs that induced sustained MAP increases 
exhibited the lowest oxygen affinity whereas less vasoactive HBOCs exhibited the 
highest oxygen affinity (Rohlf et al., 1998).  On the contrary, Olson et al. (Olson et al., 
2003) also conducted studies using cross-linked tetramers that demonstrated that there is 
no significant decrease in vasoconstriction or MAP response when the oxygen affinity of 
HBOCs is increased.  Instead, they found that there was a strong correlation between the 
rise in total peripheral resistance (TPR) and the rate of NO interaction with hemoglobin. 
 Endothelins are a family of peptides which comprises endothelin-1, endothelin-2, 
and endothelin-3.  Endothelin-1 is a potent vasoconstrictor generated mainly in 
endothelial cells.  Some of its hypertensive effects can be attributed to its direct influence 
on the renin-angiotensin-aldosterone system.  ET-1 also interacts with two receptor types, 
the ETA and ETB.  ETA receptors are localized in the smooth muscle cells while ETB 
receptors are located on endothelial cells and smooth muscle cells.  Activation of ETA 
receptors by ET-1 induces a slow and long acting vasoconstriction.  ET-1 and ET-3 
equally interact with ETB receptors inducing a transient increase in NO production 
resulting in vasodilation (Agapitou and Haynes, 2002).  Some studies demonstrated that 
ETA receptor antagonists substantially inhibited the pressor activity elicited by diaspirin 
crosslinked Hb (Rioux et al., 1999, Gulati et al. 1994).  However, some studies have 
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found conflicting results using endothelin converting enzyme inhibitors.  These studies 
found no effect on the pressor effects elicited by diaspirin crosslinked Hb (Schultz et al., 
1993, Gulati et al., 1995). 
The most widely accepted explanation for vasoconstriction is NO scavenging.  
NO is a known EDRF (endothelial-derived relaxing factor) and therefore changes in NO 
have predictable effects on vascular smooth muscle tone.  NO interacts with deoxy-Hb 
with picomolar affinity and reacts irreverisibly with oxyhemoglobin to form nitrate (NO3-
) and MetHb (Rohlfs et al., 1998).  These reactions occur at bimolecular rate constants of 
30 –50 µM-1s-1 at 37 oC (Eich et al., 1996).  The rate of these reactions could account for 
the rapid rise in TPR.  It has also been suggested that oxygen-linked S-nitrosylation 
reactions of Hb may also regulate vascular tone (Jia et al., 1996).  This occurs by S-
nitrosothiols interacting with the cysteine 93 residue in the Hb beta subunit.  However, 
the rate of this reaction seems to be too slow to account for the observed immediate 
increases in MAP and vasoconstriction. 
NO interactions with Hb would lead one to believe that red blood cells (RBCs) 
should be the ‘black holes’ of the vascular system.  These interactions have been found to 
be diffusion limited in RBCs.  Azarov et al. conducted studies that showed NO 
interacting with intact RBCs was slower by a factor of ~1,000 compared with free Hb 
(Azarov et al., 2005).  Therefore, free Hb can scavenge NO and therefore greatly affect 
vascular tone.  In addition, it is believed that a fraction of HBOCs may extravasate and 
scavenge NO in the perivascular space.  Sampei et al. (Sampei et al., 2005 ) conducted 
studies comparing the effects of HBOCs on tight endothelial junctions found in cranial 
pial arterioles to the less permeable vessels found in skeletal and ventricular muscle.  
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They concluded that HBOCs do not scavenge sufficient NO in the plasma to significantly 
affect baseline tone in vascular beds with tight endothelial junctions, but do produce 
substantial constriction in vascular beds with porous endothelium (Sapmei et al., 2005). 
Other studies also support this theory.  Sikai et al. (Sakai et al., 2000) found that larger 
polymer HBOCs resulted in less vasoconstriction and hypertension presumably due to 
less extravasation (Sakai et al., 2000). 
Further studies focusing on different HBOCs have provided more evidence 
supporting the NO scavenging hypothesis.  Pawson et al. (Pawson et al., 2007) 
demonstrated that the non-specific NO synthase inhibitor L-NAME induced similar 
vasoactivity to that of HBOC 201.  When simultaneously administered, there was no 
further enhancement of constriction (Pawson et al., 2007).  Many studies have used 
recombinant Hb that varies in P50 and NO reactivity to test the two competing theories of 
the HBOC-induced pressor effect.  A correlation was observed between the rate of NO 
reactivity, but not P50 (Doherty et al., 1998, Olson et al., 2003).  These data support the 
NO scavenging hypothesis. 
There have been some studies that indicate that NO scavenging may not be 
responsible for the pressor effects.  Fitzpatrick el al. collected arterial NO concentration 
samples that did not seem to significantly change with administration of HBOC 201 
(Fitzpatrick et al., 2004).  However, they also measured an increase in the metHb level 
which suggests that NO was interacting with HBOC 201.  A non-significant decrease in 
NO levels was observed, which may be attributed to HBOC 201 interacting with NO with 
a compensatory increase in NO output.  Recently, Tsai et al. (Tsai et al., 2006) utilized 
NO electrodes to measure NO directly in the perivascular space in response to a variety 
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of HBOCs.  Their results indicate a decrease in NO in the perivascular space in response 
to all HBOCs, however, the largest MW HBOC tested did not induce vasoconstriction.  
They suggested that factors such as molecular dimension, retention time, and gas-carrying 
properties are more likely to regulate vascular tone (Tsai et al., 2006). 
Biochemistry of NO 
Nitric Oxide Properties and Roles 
 NO is a unique signaling molecule because of its various chemical properties.  It 
is perhaps these chemical properties that allow it to have such diverse physiological 
functions in the human body.  These functions may be attributed to its ability to act as 
either a Lewis acid or Lewis base.  It can also act as either an oxidizing or reducing agent 
due to its intermediate oxidation state.  Its short half-life of only a few seconds and its 
ability to freely diffuse through tissues also makes it an ideal messenger (Ignarro, 1990, 
Lane et al., 2002). 
 The physiological functions of NO have only recently been better defined.  With 
respect to the present study, NO has been found to activate soluble guanylate cyclase by 
heme-dependent mechanisms.  The NO-heme moiety is responsible for enzyme 
activation (Ignarro, 1990).  This activation increases cGMP which in turn activates a 
kinase cascade that decreases intracellular Ca2+.  This sequence attenuates contractile 
tone and contributes to vasodilation (Lane et al., 2002).  NO has also been found to be 
important in immunosuppression.  NO is released by macrophages and neutrophils when 
necessary.  The rapid oxidation of NO to both nitrate and nitrite is associated with the 
killing of phagocytized microorganisms at higher concentrations of NO.  Additionally, 
this local release of NO has been found to partake in an inflammatory response by 
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inhibiting platelet aggregation and improving local blood flow.  The latter mechanisms 
are less relevant with respect to the present study, but show how the diverse chemical 
properties of this signaling molecule correspond to its diverse physiological functions. 
Nitric Oxide Synthesis and Regulation 
 The enzyme that is responsible for the synthesis of NO is NO synthase (NOS). 
Three isoforms of NOS have been identified. nNOS (NOS1) and eNOS (NOS3) are Ca2+-
dependent forms whose expression can be either constitutive or regulated.  nNOS is 
expressed in neurons and eNOS is expressed in endothelial cells, cardiac myocytes, and 
blood platelets.  The third isoform is commonly known as iNOS (NOS2).  Its expression 
is regulated by cytokines. 
 Co-translational modifications render eNOS membrane-bound unlike the 
cytoplasmic nNOS and iNOS isoforms.  The localization of eNOS with the membrane of 
endothelial cells makes it a prime candidate for further review.  eNOS activity is 
regulated at the transcriptional and post translational level.  Transcription of eNOS has 
been found to be influenced by many factors including shear stress, sterol regulatory 
elements, estrogen-responsive elements, cAMP-responsive elements, erythropoietin, 
hypoxia, and NO itself.  Post-translational regulation includes eNOS palmitoylation and 
serine phosphorylation.  These regulate the stability, localization, and activity of eNOS.  
The Ca2+-dependency of eNOS also permits many hormones to affect its activity such as 
bradykinin, VEGF, and histamine (Gosink et al., 1993, Papapetropoulos et al., 1997, 
Kelm et al., 1993). 
 The regulation of NOS is complex, while the production of NO is more 
straightforward.  eNOS (and nNOS) contains binding sites for heme and calmodulin 
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which are both essential for enzyme activation (Govers et al., 2001). Upon Ca2+-bound 
calmodulin interacting with eNOS, NADPH donates electrons at the reductase domain.  
These electrons are subsequently shuttled through the calmodulin-binding domain toward 
the heme-containing eNOS oxygenase domain, which results in the formation of citrulline 
and NO (Abu-Soud et al., 1993). 
Nitric Oxide Sources 
 There are various known sources of NO that may contribute to vascular tone.  The 
vascular endothelium is believed to be the predominant source of NO.  Endothelial cells 
express basal levels of NO and therefore can help maintain homeostasis based upon the 
NOS regulation discussed previously.  nNOS produces NO in neurons which have been 
found to innervate the vasculature to some degree in rats (Toda et al., 2003).  Kavdia and 
Popel demonstrated that NO release by nNOS would significantly affect available smooth 
muscle NO (Kavdia and Popel, 2004).  Myocytes contain eNOS which suggests they too 
may be involved in localized vascular reactivity, but there has yet to be any conclusive 
evidence to support this.  There has been some debate over whether nitrites and S-
nitrosothiols (SNO) also act as NO reserves.  SNO plasma levels have been recorded in 
the 10 nM range (Cosby et al., 2003).  SNO production has been determined to occur in 
albumin and Hb.  In albumin, the copper and sometimes heme can facilitate S-
nitrosylation by NO.  Hb can react with NO and nitrite to produce SNO-Hb.  Hb most 
likely out-competes albumin for NO, but this outcome is dependent on the rate and 
amount of NO that is made available.  It has been found that at higher levels of NO, Hb 
breaks NO down into metHb and nitrate (Stamler, 2004).  Plasma nitrite levels range 
from 150-1000 nM.  This vast pool for NO has been proposed to be converted by either 
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enzymatic reduction or nonenzymatic disproportionation.  Cosby et al. found that nitrite 
levels decrease upon NOS inhibition while others have also found that nitrite is 
consumed during exercise (Cosby et al., 2003).  Only deoxyHb converts nitrite to NO 
(and met Hb).  These observations seem to make nitrite and ideal source of NO in a 
hypoxic environment. 
 In summary, there are many NO sources available.  Endothelial, neuronal, and 
muscular NO production engender paracrine and autocrine effects on the vasculature.  
The stability of SNO and nitrite allow NO to engender endocrine effects as well.  The 
combined complexity that all these factors have on the vasculature is just beginning to be 
understood. 
Nitric Oxide Metabolism 
 Endogenous NO has a biological half-life of 3-5 seconds.  The majority of NO is 
oxidized to NO2-.  A small portion is converted to NO3-.  The metabolism of NO is also 
inversely related to superoxide anion concentration.  In vivo, the superoxide anion 
concentrations are minimal due to the high activities of superoxide dismutase.  NO may 
also react with Hb in RBCs to form MetHb and biologically inactive nitrate; however, 
this reaction is diffusion-limited (Buerk, 2007).  Any free Hb from lysed RBCs is more 
accessible to degrade NO.  The ability of NO to diffuse easily through tissues and its 
oxygen-catalyzed inactivation are primarily responsible for NO metabolism (Ignarro, 
1990). 
Purposeof the Present Study 
 
 The purpose of the present study was to investigate and compare the vasoactive 
properties of three different HBOCs: HBOC 201, HBOC 205 MW 400, and HBOC 205 
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600.  The vasoactive properties were based on observations of mean arterial pressure and 
vessel diameters in the spinotrapezius muscle of the rat.  The present study also set out to 
elaborate and quantify the interactions of HBOCs with NO, as well as the degree of 
HBOC extravasation. 
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MATERIALS AND METHODS 
Anesthesia and Animal Preparation 
 The experiments were approved by the Institutional Animal Care and Use 
Committee of Virginia Commonwealth University and were conducted on 10-wk-old 
200-275 g male Sprague-Dawley rats (Harlan, Indianapolis, IN, N = 67).  Rats were 
housed in a vivarium under controlled conditions (temperature 20-23 oC, humidity 40-60 
%, 12/12 hour light/dark cycle).  Free access to food and water were maintained under 
the supervision of a certified animal technician. 
 Prior to experimentation, rats were anesthetized with an intraperitoneal injection 
of a ketamine and acepromazine mixture (75 mg/kg of ketamine and 2.5 mg/kg of 
acepromazine, Henry Schein, Melville, NY).  A continuous (0.254 ml/hr) intravenous 
infusion of Alfaxan (Alfaxalone 10 mg/ml, Abbeyvet Export LTD, North Yorkshire, 
England) via the left cannulated jugular vein was utilized to maintain anesthesia for the 
remainder of the experiment.  The animal was placed on a homeothermic blanket set at 
40 oC to maintain body temperature at 37 oC.  Upon completion of the experiment, the 
animal was euthanized with Euthasol (pentobarbital 390 mg/ml and phenytoin 50 mg/ml, 
Delmarva Laboratories Inc., Midlothian, VA). 
Surgical Procedures 
 A tracheostomy was utilized to insure a patent airway.  A small midline incision 
was made in the anterior neck over the trachea.  The subcutaneous tissue was dissected 
and the sternohyoid muscle was split longitudinally by blunt dissection to expose the 
trachea.  The trachea was isolated, incised, and cannulated with PE 240 tubing.  The skin 
incision was then extended inferiorly and to the left in order to expose the jugular vein as 
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it passed over the clavicle.  The jugular vein was cannulated with PE 10 tubing for 
continuous (0.254 cc/hr) infusion of Alfaxan.  Maintenance of a surgical plane of 
anesthesia was observed via absence of a toe pinch reflex and stable vital signs (mean 
arterial pressure and respiratory rate).  The left carotid artery was then exposed in the 
crease between the sternohyoid muscle and the mastoid portion of the sternocephalic 
muscle.  The left carotid artery was cannulated with PE 50 tubing to allow continuous 
MAP measurements and collection of arterial blood samples.  The left femoral vein was 
cannulated with PE 10 tubing for infusion of experimental agents.  Patency of vascular 
cannulae was maintained with either a heparin lock (20 units of heparin/ml of 0.9 % 
normal saline) or continuous infusion. 
The left spinotrapezius muscle was utilized for microcirculatory observations 
using surgical preparations described by Gray (Gray, 1973).  A midline incision was 
made on the dorsal side at the level of the lumbar vertebrae and extended superiorly to 
the scapula.  The subcutaneous connective tissue was carefully dissected to avoid trauma 
and bleeding of the underlying spinotrapezius muscle.  Bleeding was prevented or 
minimized by using a low-temperature cautery device (Gemini RS-300, Roboz Surgical 
Instrument CO., Rockville, MD).  The muscle was kept moist with frequent applications 
of phosphate buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO; pH 7.4).  The muscle 
was separated from the surrounding deeper tissues and sutured around the periphery with 
5-0 silk fastened at ~ 1 cm intervals.  These sutures allowed for the muscle to be 
surgically manipulated and firmly attached to the custom-made thermostable microscope 
platform for microscopic observation as described by Golub and Pittman (Golub and 
Pittman, 2003) and modified by Lowman (Lowman, 2004) .  This method of preparation 
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leaves the supplying nerve and vasculature intact.  The muscle tissue was moistened with 
PBS and covered with plastic film (Saran, Dow Corning Midland, MI) to minimize 
desiccation and atmospheric gas exchange. 
Measurements 
 Mean arterial blood pressure (MAP) was measured through the carotid artery 
catheter which was connected to a CyQ 103/301 display system (CyberSense Inc., 
Nicholasville, KY).  The system gave a continuous reading of MAP, which was recorded 
every 5 minutes and averaged for all periods in the study. 
Blood sampling (2 x 55 µl) was utilized to determine hematocrit, arterial blood 
gas measurements (ABL 705, Radiometer America Inc., Westlake, OH), and 
Hb/oxygenation status (OSM3 Hexoximeter, Radiometer, Copenhagen, DK). 
Microscopic measurements were made using an Axioplan-2 microscope (Zeiss, 
Thornwood, NY) equipped with Achroplan objectives).  The microscope was connected 
to a CCD camera (Cool Snap cf, Roper Scientific, Tucson, AZ) and a computer (Dell 
Dimension 8250, Dell), which was used for acquiring images of the microcirculation.  
Diameter measurements were made directly over the image generated.  A 100-watt 
halogen lamp was used to transilluminate the muscle preparation.  A 10X objective  was 
used to obtain images for determination of the internal diameter of microvessels. 
Solutions 
Pharmacological Agents 
 Experiments were conducted to examine the vasoactivity of HBOC 201, HBOC 
205 MW 400, and HBOC 205 MW 600 (kindly provided by Biopure Corp., Cambridge, 
MA).  A plasma HBOC dose range of 0.01, 0.1, 1.0, 10, 100 µM was utilized to assess 
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vasoactivity.  Doses were dependent on plasma volume.  The physicochemical properties 
of Hb products were characterized by THb, oxyHb, MetHb, oxyHb, osmolality, MW, and 
oxygen affinity. 
 Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME, Sigma-Aldrich 
Corporation, St. Louis, MO) was utilized to mimic HBOC vasoactivity.  A stock solution 
of 200 mg of L-NAME in 10 ml of 0.9 % normal saline was made.  An intravenous bolus 
of 5 mg/kg was given to achieve the desired vasoactivity. 
 A dose range of NaNO2 (10, 100, 1000, 3000 µM) was utilized to compensate for 
increased vasoconstriction and MAP (Sigma-Aldrich Corporation, St. Louis, MO).  
Doses were dependent on blood volume. 
Conjugated TRITC-HBOC Solution 
 Tetramethyl-rhodamine-isothiocyanate (TRITC, Sigma-Aldrich Corporation, St. 
Louis, MO) was utilized to tag HBOC 201 and HBOC 205 MW 600.  Two ml of HBOC 
were combined with 0.5 ml of concentrated carbonate-bicarbonate buffer (prepared 
according to directions; pH = 9.4, C-3041, Sigma-Aldrich, St. Louis, MO) and 5 mg 
TRITC (with 1 drop DMSO added, Research Organics Inc., Cleveland, OH).  The 
solution was deoxygenated by bubbling with nitrogen gas.  The solution was then sealed 
with Parafilm, covered with aluminum foil for light protection, and stirred for 2 hours. 
The mixture was then dialyzed to remove excess unbound TRITC.  The labeled 
HBOC was sealed in Spectra/Por 4 molecular porous membrane tubing (diameter 16 mm, 
Spectrum Laboratories, Rancho Dominguez, CA; MWCO = 12-14 kDa) and placed into a 
beaker containing 10.75 g Polyvinylpyrrolidone (PVP, Aldrich Chemical Co., 
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Milwaukee, WI; MW = 55 kDa) dissolved in 125 ml PBS.  The beaker containing the 
dialysis tubing was continuously stirred for 18 hours in the absence of light. 
 
Subsequently, the mixture was transferred from the dialysis bag into a 15 ml cone 
tube and centrifuged at 4000 rpm for 4 minutes in a high speed microcentrifuge (Jouan, 
Winchester, VA).  The clear supernatant was then transferred in 0.5 ml aliquots into 
Click-Snap PCR tubes and placed in a 2-5 oC refrigerator for later use. 
Calculations 
Blood volume was determined as 6 % of the body weight (Costanzo, 2006).  Plasma 
Volume was determined as blood volume times (1- Hct). 
Experimental Protocols 
In Vivo 
Prior to experimental collections for all studies, blood gas measurements, 
Hb/oxygen saturation, and hematocrit were recorded via blood sampling.  A 30-minute 
equilibration period was allowed to normalize the animal prior to blood sampling.  
Baseline vessel diameter and MAP measurements were recorded prior to experimental 
infusions.  During experimental periods, diameter and MAP measurements were recorded 
manually every 5 minutes.  The initial experimental infusion was marked as time 0.  
Experimental agents were infused via the femoral vein at 0.01 ml/s.  After the 
experiment, blood gas measurements (Appendix VI) and Hb/oxygen saturation were 
again recorded. 
Vasoactivity Response to Topload HBOC 201, HBOC 205 MW 400, HBOC 205 MW 600 
Infusion 
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 Sprague-Dawley rats (N = 6, N=6, N=6) received a HBOC 201, 205 MW 400, 
and 205 MW 600 topload, respectively, (0.01, 0.1, 1.0, 10.0, 100.0 µM) systemically via 
the left jugular vein.  Vessel diameter and MAP were noted pre-treatment (i.e., baseline), 
and subsequently every 5 minutes post-treatment for 70 minutes.  Volume top-loading 
with 5.9 % human serum albumin was used to test whether increases in plasma volume 
had any effect on vessel diameter and MAP (N=7). 
Effect of NaNO2 on Vessel Diameter and MAP in the Presence of HBOC 201 and HBOC 
205 MW 600 Infusion 
 
 A first group (N=6) received HBOC 201 (100 µM) at time 0.  At t = 15 min, a 
dose response of NaNO2 (10, 100, 1000 µM) was infused intravenously via the right 
femoral vein.  This protocol was repeated with HBOC 205 MW 600 (N=6).  HBOC 201 
and 205 MW 600 were infused in the absence of NaNO2 to test their vasoactive longevity 
(N=2, N=2, respectively).  In all groups, vessel diameter and MAP were noted pre-
treatment, and subsequently every 5 minutes post-treatment for 65 minutes. 
Effect of NaNO2 on Vessel Diameter and MAP in the Absence of HBOC 201 and HBOC 
205 MW 600 Infusion 
 
 Sprague-Dawley rats (N=6) received a series of NaNO2 doses (10, 100, 1000 µm, 
estimated plasma concentration) at t=0 via the right femoral vein.  Vessel diameter and 
MAP were noted pre-treatment, and subsequently every 5 minutes post-treatment for 65 
minutes. 
Effect of Concomitant NaNO2 and HBOC 205 MW 600 Infusion on Vessel Diameter and 
MAP 
 
 Rats received a bolus dose of 100 µM HBOC 205 MW 600 and 3000 µM NaNO2 
at time 0 (N=5). Vessel diameter and MAP were noted pre-treatment, and subsequently 
every 5 minutes post-treatment for 55 minutes. 
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Effect of NaNO2 on Vessel Diameter and MAP in Presence of L-NAME 
 Sprague-Dawley rats (N=6) received an intravenous bolus of L-NAME (5 mg/kg).  
After a 25 minute period to assure L-NAME’s maximal effect, a sequence of doses of 
NaNO2 (10, 100, 1000, 3000 µM, estimated plasma concentration) was infused 
intravenously.  L-NAME was infused in the absence of NaNO2 to test its longevity 
(N=2).  Vessel diameter and MAP were noted pre-treatment, and subsequently every 5 
minutes post-treatment for 85 minutes. 
HBOC 201 and HBOC 205 MW 600 Extravasation 
 Before and after experimentation, a site consisting of arterioles and venules was 
photographed using IP Lab Software (Scanalytics, Inc., Fairfax, VA) (N=3, N=3, 
respectively).  HBOC 201 and 205 MW 600 were labeled with TRITC and infused at 
time 0 (50 µM).  Images were recorded using a green filter every second for 2 minutes 
using IP Lab software.  Subsequently, images were recorded every minute for 5 minutes 
and then every 5 minutes for 20 minutes. 
In Vitro 
HBOC 201 and HBOC 205 MW 600 NO Consumption 
 An Amino 700 NO electrode (Innovation Instrument Inc. Tampa, FL) was utilized 
to determine NO consumption rates of HBOC 201 and HBOC 205 MW 600.  The NO 
electrode was submerged in deionized H20 overnight and then polarized in PBS for two 
hours at +0.9 mV.  Calibration of the electrode was then conducted using nitrogen, 650 
nM NO (392 ppm), and 1300 nM NO (818 ppm).  The chamber NO concentration was 
measured with the NO electrode and based on a linear calibration curve.  The calibration 
and experiment were run at room temperature (27 oC). 
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A mutli-port measurement chamber (World Precision Instruments, Inc. Sarasota, 
FL) was filled with 1 mL fluid volume.  NO and HBOC concentrations were calculated to 
mimic in vivo studies (NO: 650 nM, HBOC: 0.1, 1.0, 10, 100 µM).  Data were collected 
using a Keithley picoammeter (Keithley Instruments Inc. Cleveland, OH) with Excel 
software. 
Three trials were run for each HBOC tested.  The first step was conducted using a 
650 nM NO solution.  This solution was then utilized to test the NO consumption of 
HBOC 201 and HBOC 205 MW 600 (0.1, 1.0,10, 100 µM).  The chamber was cleaned 
and refilled with the 650 nM NO solution for each subsequent dose of HBOC. 
Statistical Analysis 
 Control and experimental groups were analyzed and compared using one-way 
ANOVA statistics and paired t-tests.  Data are reported as mean + standard error (SE) and 
P < 0.05 was regarded as statistically significant. 
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RESULTS 
Vasoactivity Response to Topload HBOC 201, HBOC 205 MW 400, HBOC 205 MW 600 
Infusion 
 
First, a topload of 5.9 % albumin was utilized to verify that volume expansion was not 
significantly affecting MAP and vessel diameters (Figure 1).  As depicted in Figure 2A, the 
topload infusion of HBOC 201 (0.01, 0.1, 1.0, 10.0, 100.0 µM) increased MAP significantly at 
the higher doses of 10 and 100 µM from 96 + 6 to 117 + 3 and 135 + 5 mmHg, respectively (P < 
0.01, P < 0.001).  This was equivalent to a 22.4 + 5.9 and 42.5 + 10.2 % increase, respectively 
(Figure 3A).  In Figure 2B, the topload infusion of HBOC 201 decreased vessel diameters at 100 
µM from 122 + 5 to 104 + 5, 70 + 2 to 60 + 3, and 34 + 2 to 28 + 1 µm (P < 0.05, P < 0.01, P < 
0.05, respectively)  This was equivalent to a 13.9 + 3.4, 14.3 + 4.5, and 15.8 + 4.3 %, 
respectively (Figure 3B, C, D). 
As depicted in Figure 4A, the topload infusion of HBOC 205 MW 400 (0.01, 0.1, 1.0, 
10.0, 100.0 µM) increased MAP significantly at higher doses of 10 and 100 µM from 105 + 4 to 
132 + 6 and 142 + 7 mmHg, respectively (P < 0.01, P < 0.001, respectively).  This was 
equivalent to a 25.4 + 3 and 34.8 + 4.9 % increase, respectively (Figure 5A).  In Figure 4B, at 10 
µM, vessel diameters decreased from 124 + 4 to 105 + 8 69 + 3 to 61 + 4, and 40 + 1 to 35 + 3 
µm (P < 0.05)  This was equivalent to a 14.8 + 6.3, 8.5 + 3.9, and 6.7 + 3.8 % decrease (Figure 
5B, C, D).  At 100 µM, vessel diameters decreased further to 88 + 5, 69 + 3 to 56 + 4 and 40 + 1 
to 32 + 2 µm (P < 0.001, P < 0.01, P < 0.01, respectively).  This was equivalent to a 28 + 5.1, 
18.6 + 3.6, and 20.0 + 5.0 % decrease (Figure 5B, C, D). 
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Figure 1.  Response of MAP and Arteriolar Diameter to HSA (N=7). A topload infusion of 
human serum albumin (HSA) did not alter MAP (A) or arteriolar diameter (B) by means of 
volume expansion. 
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Figure 2.  Response of MAP and arteriolar diameter to HBOC 201 (N=6). A) MAP significantly 
increased at 10.0 µM and 100 µM concentrations of HBOC 201.  B) Large, intermediate, and 
small arteriolar diameters significantly decreased in response to HBOC 201 at 100 µM (*P < 
0.05, **P < 0.01, ***P < 0.001). 
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Figure 3.  % Change in MAP and arteriolar diameter in response to HBOC 201 (N=6).  A) There 
was a significant % change in MAP at 1.0, 10, and 100 µM (P < 0.05).  B) There was a 
significant % change in large vessel diameter at 100 µM (P < 0.05).  C) There was a significant 
% change in intermediate vessel diameter at 10 and 100 µM. D) There was a significant % 
change in small vessel diameter at 100 µM. (*P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 4.  Response of MAP and arteriolar diameter to HBOC 205 MW 400 (N=6). A) MAP 
significantly increased at 10.0 µM and 100 µM concentrations of HBOC 205 MW 600.  B) 
Large, intermediate, and small arteriolar diameters significantly decreased in response to HBOC 
201 at 100 µM (*P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 5.  % Change in MAP and arteriolar diameter in response to HBOC 205 MW 400.  
Response of MAP and arteriolar diameter to HBOC 205 MW 400 (N=6). A) MAP significantly 
increased at 1.0, 10.0 and 100 µM concentrations of HBOC 205 MW 400.  B, C, D) Large and 
intermediate arteriolar diameters significantly decreased in response to HBOC 201 at 10 and 100 
µM.  Small arteriolar diameter significantly decreased in response to HBOC 201 at 0.1, 1.0, 10, 
and 100 µM. (*P < 0.05, **P < 0.01, ***P < 0.001). 
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As depicted in Figure 6A, the topload infusion of HBOC 205 MW 600 (0.01, 0.1, 1.0, 
10.0, 100.0 µM) increased MAP significantly at higher doses of 10 and 100 µM from 92 + 5.3 to 
121 + 4.4 and 138 + 4.9 mmHg, respectively (P < 0.01, P < 0.001).  This was equivalent to a 
31.6 + 3.4 and a 50 + 4.2 % increase in vessel diameter, respectively (Figure 7A).  In Figure 6B, 
the topload infusion of HBOC 205 MW 600 decreased arteriolar diameters at 100 µM from 122 
+ 6.5 to 106 + 6.6, 70 + 2.4 to 64 + 3.2, and 36 + 1.5 to 27 + 2.3 (P < 0.05, P < 0.05, P < 0.01).  
This was equivalent to a 10.5 + 4.6, 8.9 + 3.9, and 25.7 + 6.5 % decrease, respectively (Figure 
7B). 
 
Effect of NaNO2 on Vessel Diameter, MAP, and Blood Constituents in the Presence and Absence 
of HBOC 201, HBOC 205 MW 600, and L-NAME Infusion 
 
In the presence of HBOC 201 (100 µM), a sequence of NaNO2 doses (10, 100, 1000 µM) 
reduced MAP at 1000 µM from 143 + 5 to 115 + 7.9 mmHg (Figure 8A, P < 0.01).  This dose 
did not induce complete compensation to baseline MAP of 99 + 3 mmHg.  Arteriolar diameters 
increased slightly, although not significantly, from 112 + 5, 61 + 3, and 33 + 1 µm at 1000 µM 
(Figure 8B). 
In the presence of HBOC 205 MW 600, a sequence of NaNO2 doses (10, 100, 1000, and 
3000 µM) at 100 µM HBOC reduced MAP from 139 + 3 to 130 + 4 mmHg (Figure 9A, P < 
0.05).  At 1000 µM, NaNO2 reduced MAP to 120 + 3 mmHg (P < 0.001).  At 3000 µM, NaNO2 
reduced MAP back to baseline levels of 103 + 3 mmHg (P < 0.001).  Large arteriolar diameters 
increased from 105 + 7 to 122 + 2 µm at 3000 µM of NaNO2 (P < 0.05).  Intermediate and small 
arterioles returned to baseline diameters increasing from 56 + 5 to 70 + 4 and 30 + 2 to 35 + 3 
µm at 3000 µM NaNO2 (Figure 9B). 
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Figure 6.  Response of MAP and arteriolar diameter to HBOC 205 MW 600 (N=6).  A) MAP 
significantly increased at 10.0 µM and 100 µM concentrations of HBOC 205 MW 600.  B) 
Large, intermediate, and small arteriolar diameters significantly decreased in response to HBOC 
201 at 100 µM (*P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 7.  % Change in MAP and Arteriole Diameter in Response to HBOC 205 MW 600 
(N=6).  A) MAP significantly increased at 1.0, 10.0 uM and 100 uM concentrations of HBOC 
205 MW 600.  B) Large and intermediate arteriole diameters significantly decreased in response 
to HBOC 201 at 10 and 100 uM.  Small arteriole diameters significantly decreased in response to 
HBOC 201 at 1.0, 10, 100 uM. (*P<.05, **P<.01, ***P<.001). 
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Figure 8.  Response of MAP and arteriolar diameter to HBOC 201 and NaNO2 (N=6).  A) 
HBOC 201 significantly increased MAP.  MAP significantly decreased at 1000 µM NaNO2.  B) 
HBOC 201 significantly decreased arteriolar diameters.  Arteriolar diameters increased slightly 
at 1000 µM NaNO2. (*P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 9.  Response of MAP and arteriolar diameter to HBOC 205 MW 600 and NaNO2 (N=6).  
A) MAP increased significantly in response to HBOC 205 MW 600 (P <.05) and returned to 
baseline upon administration of 3000 µM NaNO2.  B) HBOC 205 MW 600 significantly 
decreased arteriolar diameters.  Large arteriolar diameter increased significantly at 3000 µM 
NaNO2. Intermediate and small arteriolar diameters returned back to baseline at 3000 µM 
NaNO2. (*P < 0.05, **P < 0.01, ***P < 0.001).  
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In the absence of NaNO2, HBOC 201 and HBOC 205 MW 600 maintained an elevated 
MAP and constricted arterioles for the entirety of the experiment (see Figure 10 and 11).  In the 
absence of HBOC, a sequence of doses of NaNO2 (10, 100, 1000, 3000 µM) reduced MAP at 
1000 and 3000 µM from 90 + 3 to 83 + 3 and 75 + 4 mmHg, respectively (Figure 12A, P < 0.05).  
Vessel diameters increased slightly at 3000 µM NaNO2 in larger and intermediate arterioles, 
although not significantly.  Smaller arteriolar diameter increased from 39 + 1 to 50 + 7 µm 
(Figure 12B, P < 0.05).  This was equivalent to a 28 + 17 % increase (Figure 13D). 
Table 1 shows the initial and final OSM3 values for control and experimental groups.  In 
the absence of NaNO2, HBOC 201, HBOC 205 MW 400, and HBOC 205 MW 600 significantly 
increased the % metHb from 0.52 + 0.18 to 0.83 + 0.18, 0.25 +0.04 to 0.4 +0.07, and 0.47 + 0.11 
to 0.75 + 0.14, respectively (P < 0.05).  In the presence of HBOC 201, NaNO2 further increased 
the % metHb from 0.4 + 0.1 to 0.95 + 0.38 % (P < 0.05).  In the presence of HBOC 205 MW 
400, NaNO2 further increased the % metHb from 0.54 + 0.17 to 1.13 + 0.23 % (P < 0.05).  In the 
presence of L-NAME, NaNO2 further increased the % metHb from 0.24 + 0.04 to 1.26 + 0.08 % 
(P < 0.05).  In the presence of a NaNO2 alone, the % metHb increased from 0.28 + 0.18 to 1.15 + 
0.27 % (P < 0.05). 
Rats infused with HBOCs showed an increase in total Hb concentration (Table 2).  
HBOC 201 significantly increased total Hb concentration from 13.38 + 0.65 to 15.7 + 0.46 (P < 
0.05).  HBOC 205 MW 400 increased total Hb concentration from 13 + 0.5 to 14.3 + 0.62 (P < 
0.05).  HBOC 205 MW 600 increased total Hb concentration from 14.4 + 0.3 to 14.9 + 0.25. 
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Figure 10.  HBOC 201 Longevity (N=2).  A) A 100 µM HBOC 201 infusion maintained an 
elevated MAP for 65 minutes.  B) A 100 µM HBOC 201 infusion maintained constricted large 
and intermediate arteriolar diameters for 65 minutes. 
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Figure 11.  HBOC 205 MW 600 Longevity (N=2).  A) A 100 µM infusion of HBOC 205 MW 
600 maintained an elevated MAP for 65 minutes (*P < 0.05).  B)  A 100 µM HBOC 205 MW 
600 infusion maintained constricted large, intermediate, and small arteriolar diameters for 65 
minutes. 
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Figure 12.  Response of MAP and arteriolar diameter to NaNO2 (N=6).  A) A 1000 and 3000 
µM NaNO2 dose significantly decreased MAP.  B) Arteriolar diameters increased slightly with 
increasing concentrations of NaNO2, although only small arteriolar diameter increased 
significantly at 3000 µM NaNO2. (*P < 0.05). 
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Figure 13.  % Change in MAP and arteriolar diameter in response to NaNO2 (N=6).  A) MAP 
significantly decreased at 10.0 and 100 µM concentrations of NaNO2.  B) Large arteriolar 
diameter significantly increased in response to 1000 and 3000 µM NaNO2.  Small arteriolar 
diameter significantly increased in response to 100, 1000, and 3000 µM NaNO2. (*P < 0.05, **P 
< 0.01). 
0
5
10
15
20
25
30
35
40
45
50
 
%
 C
ha
ng
e 
in
 S
m
al
l V
es
se
ls
-5
0
5
10
15
20
25
30
 
%
 C
ha
ng
e 
in
 L
ar
ge
 V
es
se
ls
B
  10 uM               100 uM              1000 uM               3000 uM      10 uM               100 uM              1000 uM              3000 uM   D
* 
** 
A
C
-30
-25
-20
-15
-10
-5
0
5
 
%
 C
ha
ng
e 
in
 M
A
P
-5
0
5
10
15
20
25
30
 
%
 C
ha
ng
e 
in
 In
te
rm
ed
ia
te
 V
es
se
ls
 ** 
 * 
** ** 
* 
 
 36
 
Table 1.  Initial and Final OSM3 values. (*P < 0.05) 
 
 
 
            
  Initial OSM3 Values   Final OSM3 Values 
 G/L tHb % SAT 
% 
HbCO %metHb Vol % O2 ct  
G/L 
tHb % SAT 
% 
HbCO %metHb Vol % O2 ct 
5.9 % Albumin Controls                   
AVE 15.10 95.73 3.77 0.27 19.27  14.7 89.57 3.17 0.27 17.70
SE 0.26 3.82 0.24 0.03 0.94  0.38 3.61 0.48 0.09 1.06
HBOC 201                     
AVE 13.38 94.23 2.65 0.52 17.05  *15.70 94.63 3.87 *0.83 20.20
SE 0.65 2.13 0.58 0.18 1.08  0.46 2.73 0.12 0.18 1.14
HBOC 205 MW 400                   
AVE 13.37 93.12 1.63 0.25 17.05  *14.30 89.50 2.42 *0.40 17.37
SE 0.60 2.20 0.45 0.04 0.99  0.61 2.23 0.55 0.07 0.94
HBOC 205 MW 600                   
AVE 13.03 89.58 2.70 0.47 15.08  *13.8 88.55 1.73 *0.75 16.63
SE 0.43 1.45 0.79 0.11 0.47  0.62 1.89 0.55 0.14 0.91
HBOC 201 + NaNO2                   
AVE 15.73 93.83 1.77 0.40 19.90  15.45 95.75 2.5 *0.95 19.9
SE 0.41 1.39 0.98 0.10 0.69     0.14      2.45       0.75        0.38              .46 
HBOC 205 MW 600 + NaNO2                 
AVE 14.42 91.90 3.04 0.54 17.78  14.93 97.28 3.35 *1.13 19.08
SE 0.30 2.91 0.49 0.17 0.77  0.25 0.95 0.60 0.23 0.44
NaNO2                       
AVE 14.33 94.88 3.68 0.28 18.17  13.77 91.77 3.58 *1.15 16.60
SE 0.37 2.92 0.10 0.18 0.84  0.34 2.77 0.14 0.28 0.82
L-NAME + NaNO2                   
AVE 14.94 95.88 3.7 0.24 21.72  14.22 82.66 3.12 *1.26 17.84
SE        .47      1.55      0.10       0.04            0.66     0.23      3.36       0.12        0.08              .92 
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In the presence of L-NAME, MAP increased gradually to 132 + 6 mmHg (P < 0.001).  
This was equivalent to a 37.5 + 3 % change.  Vessel diameters decreased from 110 + 5, 71 + 1, 
and 42 + 1 to 81 + 6, 62 + 2, and 34 + 1, respectively (Figure 14A, P < 0.01, P < 0.001, P < 
0.001).  This was equivalent to a 23 + 6, 13 + 4, and 20 + 4 % decrease (Figure 15A).  A NaNO2 
dose of 100 µM returned MAP back to baseline.  A 1000 µM dose of NaNO2 was required to 
return large arteriolar diameter back to baseline.  A 100 µM dose of NaNO2 was required to 
return small arteriolar diameter back to baseline, and a 10 µM dose of NaNO2 was required to 
return intermediate arteriolar diameter back to baseline (Figure 14B).  Administration of L-
NAME in the absence of NaNO2 induced a sustained hypertensive response (Figure 16, P < 
0.05). 
Effect of Concomitant infusion of NaNO2 and HBOC 205 MW 600 on arteriolar diameter and 
MAP 
 
 Concomitant infusion of NaNO2 and HBOC 205 MW 600 did not significantly alter 
MAP from baseline of 98 + 6 mmHg.  Arteriolar diameters also did not exhibit any changes from 
baseline of 114 + 2, 68 + 1, and 37 + 1 µm (Figure 17). 
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Figure 14.  Response of MAP and arteriolar diameter to L-NAME and NaNO2 (N=6).  A) L-
NAME gradually increased MAP (P < 0.001).  MAP significantly decreased at 10 µM NaNO2 
and returned to baseline at 100 µM.  MAP further decreased at 1000 and 3000 µM NaNO2 (P < 
0.01, P < 0.001).  B) L-NAME gradually decreased arteriole diameters (P < 0.01, P < 0.001, P < 
0.001).  Large arteriole diameters increased back to baseline at 3000 µM NaNO2.  Intermediate 
arteriole diameters increased back to baseline at 10 µM and small arteriole diameters increased 
back to baseline at 1000 µM.  (*P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 15.  % Change in MAP and arteriolar diameter in response to L-NAME and NaNO2 
(N=6).  A) L-NAME gradually increased MAP.  MAP returned to baseline at 100 and 1000 µM 
NaNO2 and decreased further at 3000 µM NaNO2.  B) L-NAME gradually decreased arteriolar 
diameters.  Large arterioles significantly increased in diameter at 10, 100, and 1000 µM NaNO2.  
Large arterioles returned to baseline at 3000 µM NaNO2.  Intermediate arteriolar diameter 
returned to baseline at 10 µM NaNO2.  Small arterioles returned to baseline diameter at 100 µM 
NaNO2. (*P < 0.05, **P < 0.01, ***P < 0.001). 
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Figure 16.  L-NAME Longevity (N=2).  A) L-NAME maintained an elevated MAP for 85 
minutes.  B) L-NAME maintained constricted arterioles for 85 minutes. (*P < 0.05). 
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Figure 17.  Response of MAP and arteriolar diameter to concomitant HBOC 205 MW 600 and 
NaNO2 (N=5).  A and B) Concomitant infusion of HBOC 205 MW 600 and NaNO2 did not 
significantly change MAP or arteriolar diameter. 
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HBOC 201 and HBOC 205 MW 600 Extravasation 
 
Figures 18 and 19 show the fluorescence of the TRITC-HBOC 201 at 0, 10”, 20”, 40”, 
60”, 80”, 100”, 3’,4’,5’,10’, and 15’.  Fluorescently-labeled HBOC 201 flowed through the 
arterioles and venules seconds after infusion and then was progressively concentrated at the 
vessel wall and slowly extravasated into the interstitium.  The yellow rectangle in Figure 19 
shows a cross section of both the arteriole and venule used to quantify the fluorescent intensity at 
each time point.  Figure 20 shows the intensity of this section at each time point.  It is evident 
that the fluorescent intensity increased the most in the vessel wall and surrounding interstitium.  
Figure 21 isolates three locations: the lumen, vessel wall, and interstitium.  After infusion of the 
TRITC-HBOC 201, the lumen of both arterioles and venules exhibited the fastest increase in 
intensity while the interstitium exhibited the slowest.  The luminal intensity was eventually 
surpassed by the vessel wall and interstitium intensity approximately between 80-100 seconds.  
In comparison to the venule, the intensity was highest in the arteriole in each location. 
Figure 22 and 23 show the fluorescence of the TRITC-HBOC 205 MW 600 at 0, 10”, 
20”, 40”, 60”, 80”, 100”, 3’,4’,5’,10’ and 15’.  Labeled HBOC 205 MW 600 flowed through the 
arterioles and venules seconds after infusion and then was progressively concentrated in the 
vessel wall and slowly extravasating into the interstitium.  The yellow rectangle in Figure 23 
defines the measurement region for both the arteriole and venule used to quantify the fluorescent 
intensity at each time point.  Figure 24 shows the intensity of this region at each time point.  It is 
evident that the largest increase in fluorescent intensity occurred near the vessel wall and the 
surrounding interstitium.  Figure 25 isolates three locations: the lumen, vessel wall, and 
interstitium.  After infusion of the TRITC-HBOC 205 MW 600, the lumen of both arterioles and 
venules exhibited the fastest increase in intensity, while the interstitium exhibited the slowest.  
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The luminal intensity was eventually surpassed by the intensity near the vessel wall and in the 
interstitium approximately 80-100 seconds following infusion of the labeled HBOC.  In 
comparison to the venule, the intensity was highest in the arteriole at each location. 
Effect of HBOC 201 and HBOC 205 MW 600 on NO Consumption 
 
The present in vitro study demonstrated that NO interacts with different HBOCs.  Similar 
concentrations (0.1, 1, 10, 100 µM) to those used in vivo were utilized in this study to determine 
the effect of HBOCs on the rate of NO consumption.  HBOC 201 and HBOC 205 MW 600 were 
found to scavenge NO at similar rates for similar doses.  NO was found to diffuse from the 
chamber at a slow rate of 0.239 + 0.003 nM/s.  The introduction of HBOC 201 and HBOC 205 
MW 600 into the chamber at a concentration of .1 µM increased the rate of NO consumption 
significantly to 1.708 + 0.104 and 3.059 + 0.153 nM/s, respectively (P < 0.05).  Increasing the 
HBOC’s concentration to 1 µM further increased NO consumption significantly to 5.765 + 0.409 
and 6.573 + 0.329 nM/s respectively (P < 0.05).  An increasing trend was seen with the 
subsequent doses of HBOC, however these increases were not significant (see Figure 26). 
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Figure 18.  Fluorescent Images of TRITC-HBOC 201 Infusion.  
 
 
 
 45
 
 
 
 
15’ 10’ 
5’ 4’ 
3’ 100”  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19.  Fluorescent Images of TRITC-HBOC 201 Infusion. 
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Figure 20.  Fluorescent Profile Analysis of Arteriole and Venule in Response to HBOC 201.  
The fluorescence intensity initially increased in the lumen, but the fluorescence intensity in the 
vessel wall and interstitium surpassed the luminal intensity as time progressed.  Vertical lines 
denote location of wall-lumen interface. 
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Figure 21.  Regional Fluorescent Intensity Versus Time.  A) Fluorescent intensity in the arteriole 
increased at the fastest rate in the lumen, but eventually was surpassed by the fluorescent 
intensity in the vessel wall and interstitium between 40-60 seconds.  B) Fluorescent intensity in 
the venule also increased at the fastest rate in the lumen, but eventually was surpassed by the 
fluorescent intensity in the vessel wall between 40-60 seconds and interstitium between 100-120 
seconds. 
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Figure 22.  Fluorescent Images of HBOC 205 MW 600 Infusion. 
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Figure 23.  Fluorescent Images of HBOC 205 MW 600 Infusion. 
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Figure 24.  Profile Analysis in Response to TRITC-HBOC 205 MW 600 Infusion.  The 
fluorescence intensity initially increased in the lumen, but the fluorescence intensity in 
the vessel wall and interstitium surpassed the luminal intensity as time progressed. 
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Figure 25.  Regional Intensity Versus Time.  A) Fluorescent intensity in the arteriole 
increased at the fastest rate in the lumen, but eventually was surpassed by the fluorescent 
intensity in the vessel wall and interstitium between 40-60 seconds.  B) Fluorescent 
intensity in the venule also increased at the fastest rate in the lumen, but eventually was 
surpassed by the fluorescent intensity in the vessel wall between 60-80 seconds and in the 
interstitium between 2 and 3 minutes. 
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Figure 26.  In vitro NO Consumption Rate for HBOC 201 and HBOC 205 MW 600.  
HBOC 201 and 205 MW 600 significantly increased NO consumption at .1 uM 1, 10, and 
plateau at 100 uM.   (***P<.001) concentrations.  NO consumption further increased and 
reached a
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DISCUSSION 
 
 There have been many studies investigating the vasopressor effects that HBOCs 
engender.  However, the mechanisms behind these effects are controversial.  Some 
experimenters support the hypothesis that the vasoconstriction is due to an 
overcompensating autoregulatory response due to the excessive O2 delivery caused by the 
increased availability of oxygen from cell-free Hb (Winslow, 2000, Rolhfs et al.,1998,).  
However, evidence supporting the NO scavenging hypothesis seems to be growing.  This 
study offers evidence that refutes the autoregulatory response hypothesis and explores 
certain mechanisms of NO scavenging. 
HBOC Molecular Weight 
Previous studies have found that increasing the average molecular weight of 
HBOCs reduces the vasopressor effects (Olson et al., 2003).  This is presumably due to a 
decrease in extravasation.  Other studies have found that there is no response to HBOCs 
in vessels with tight endothelial junctions, further supporting extravasation as a 
contributor to the hypertensive effect (Tsai et. al., 2006).  The present study suggests that 
increasing molecular weight is beneficial up to a point, however the percentage of 
tetramers and dimers is more indicative of vasopressor effects.  All three HBOCs that 
were tested showed similar effects on MAP and vessel diameters at similar 
concentrations (10 and 100 µM).  HBOC 201, HBOC 205 MW 400, and HBOC 205 MW 
600 contain approximately 2, 0.32, and 0.6 % tetramers and dimers, respectively, while 
the percentage of molecules greater than 500 kD is 10.6, 24, and 61 %, respectively.  
Previous studies conducted in this laboratory demonstrated that HBOC 301 induces 
similar increases in MAP and vasoconstriction at lower concentrations (1 µM).  HBOC 
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301 contains approximately 20 % dimers and tetramers while only 10 % of the molecules 
are greater than 500 kD.  This increased sensitivity to HBOC 301 and the similar 
response observed among the HBOCs presently studied indicate that the percentage of 
tetramers and dimers have a higher correlation with the observed vasopressor effects. 
Oxygen Delivery and the Autoregulatory Response 
 There still remain some advocates of the autoregulatory response theory.  This 
theory proposes that excessive O2 delivery by extracellular Hb causes vasoconstriction.  
Gregory et al. (Gregory et al., 2006) conducted studies testing HBOCs with different 
oxygen affinities.  They found no correlation between MAP and oxygen affinity.  The 
present study also provides evidence that does not support this hypothesis.  Vasopressor 
effects were observed at low concentrations of HBOC (10 and 100 µM), too low to 
provide much of an increase in oxygen delivery.  Plasma HBOC concentrations needed to 
supply significant oxygen delivery are known to be in the mM range.  Therefore, this 
study concludes that HBOC increases MAP and vasoconstriction by means other than the 
autoregulatory mechanism. 
NO Scavenging 
 Most experiments deriving conclusions of NO scavenging have been based on the 
inhibition of NOS.  Administration of L-NAME, a NOS inhibitor, resulted in vasopressor 
effects similar to those observed following administration of HBOCs.  This effect was 
more gradual than the immediate effects of HBOC because NOS inhibition does not 
immediately eliminate NO.  Administration of HBOC and L-NAME did not enhance the 
observed vasopressor effects (Rees et al., 1990).  These studies suggest that these agents 
induce such effects by means of the same mechanism.  The present study examined the 
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NO donor NaNO2 in order to further test the NO scavenging hypothesis.  A dose range of 
NaNO2 was utilized, but only at a 3000 µM concentration did NaNO2 completely abolish 
the hypertensive effects brought on by HBOC 205 MW 600.  A 3000 µM dose of NaNO2 
in the absence of HBOC did not result in an increase in vessel diameter that was 
equivalent to the compensation seen with HBOC 205 MW 600.  This is presumably due 
to a vasodilatory limit of the microcirculation in the spinotrapezius muscle.  To better 
examine the possibility of NO scavenging, L-NAME was utilized to closely mimic the 
effects of the HBOCs.  When L-NAME and a high enough dose of NaNO2 were co-
administered, complete compensation was achieved at much lower concentrations of 
NaNO2.  These results show that HBOCs must be interacting with the NO donated by 
NaNO2. 
 A significant increase in metHb was observed upon administration of HBOC 201, 
HBOC 205 MW 400, and HBOC 205 MW 600.  A larger increase was observed upon 
administration of NaNO2 in conjunction with HBOCs.  These increases in metHb provide 
further evidence supporting HBOC/NO interactions. 
 In vitro studies were conducted to offer more evidence supporting the NO 
scavenging hypothesis.  These studies also allowed a quantification of the NO 
consumption rate of HBOC 201 and HBOC 205 MW 600.  The consumption rates were 
found to be similar and progressively increased with increases in HBOC concentration.  
Theses findings coincide with the in vivo studies that demonstrated a progressive increase 
in the vasopressor response. 
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Tissue Specific Responses 
There have been many studies focusing on the vessel reactivity in response to 
particular HBOCs.  Some studies have found greater constriction in smaller vessels, 
while others have found greater constriction in larger vessels, however, the amount of 
constriction seems to be dependent on location.  For example, Pawson et al. (Pawson et 
al., 2007)found a greater response to cell-free Hb in the rat aorta versus the mesentery.  
With respect to the spinotrapezius muscle, the present study shows an equivalent 
decrease in vessel diameters ranging from small, intermediate, and large vessels which 
correlate to parallel increases in MAP.  This variation is influenced by the permeability of 
particular vessels to HBOCs (Tsai et al., 2006), but may also be due to tissue-specific 
mechanisms of maintaining vascular tone.  Some tissues may exhibit differences in NO 
production, perhaps due to fewer NOS enzymes in endothelial cells and/or possibly less 
neuronal innervation.  Particular tissues also utilize other vasoactive substances such as 
endothelin and acetylcholine (Clark and Fuch, 1997).  For example, it has been 
demonstrated in the mesentery, particularly in smaller vessels, that other EDRFs 
predominantly contribute to vascular tone (Feletou and Vanhoutt, 2006). 
This variation observed throughout the systemic system in response to HBOC 
administration seems to provide evidence against the autoregulatory response theory.  
Excessive oxygen delivery would be equally distributed to all tissues, however not all 
tissues respond similarly.  Future studies should focus on how individual tissues maintain 
vascular tone.  This area of focus may further the understanding of how HBOCs produce 
vasopressor effects. 
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HBOC Extravasation 
Many experiments have found that the vasopressor effects observed were 
influenced by HBOC molecular weight.  Experiments comparing microcirculatory tissues 
with tight endothelial junctions versus those with porous endothelia also demonstrated a 
correlation between vasopressor effects and HBOC molecular weight.  These findings 
indirectly show that extravasation of HBOC may contribute to vasopressor effects.  Some 
scientists claim that the time scale of extravasation could not be entirely responsible for 
vasopressor effects (Fitzpatrick et al., 2004).  The present study found that increases in 
total blood Hb concentration after administration of HBOC were not equivalent to the 
amount of Hb administered.  This may be due to excretion through the kidney of smaller 
molecules, but may also be due to extravasation. 
The present study focused more directly on this theory by tagging HBOC 201 and 
HBOC 205 MW 600 with TRITC.  These HBOCs are similar except that HBOC 201 has 
a smaller average molecular weight and has more tetramers and dimers.  Even so, both 
HBOC 201 and HBOC 205 MW 600 produced similar responses.  The TRITC labeled 
HBOC 201 and 205 MW 600 reached the microcirculation of the spinotrapezius muscle 
within seconds.  This corresponded to the immediate increase in MAP and 
vasoconstriction observed upon HBOC administration.  It is difficult to determine exactly 
when extravasation begins, however it definitely occurs between 0 and 40 seconds for 
both HBOC 201 and HBOC 205 MW 600.  An increase in fluorescence is observed in the 
walls of the arterioles and venules, although this increase is less pronounced in the 
venules.  After a few minutes, the extravasation seems to surpass the vessel walls and 
enter the interstitium, again with a lower fluorescence surrounding the venules.  The 
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immediate vasopressor effects cannot unequivocally be explained by extravasation, but 
are more likely due to the direct scavenging of NO from the luminal side of the vessel.  
However, extravasation into the vessel walls and interstitium is evident and any 
endogenous NO in these areas will be scavenged.  This could contribute to the longevity 
of symptoms observed upon HBOC administration. 
Conclusions 
 The present study focused on elucidating the mechanisms behind the vasopressor 
effects observed upon HBOC administration.  The data presented offer strong evidence 
that NO scavenging is a key mechanism involved in vasoconstriction in the 
spinotrapezius muscle in small, intermediate, and large arterioles.  These results do not 
offer any evidence of similar effects in microcirculatory beds of other tissues; however, it 
is hypothesized that tissues regulated by vasoactive substances other than NO may not 
respond similarly. 
The present study directly demonstrates for the first time that even trace amounts 
of tetramers and dimers extravasate.  These molecules most likely contribute to the 
longevity of the HBOC effects, but may be responsible for the immediate vasopressor 
effects as well.  Future studies should focus on pure HBOCs that contain no tetramers or 
dimers to further examine the effects of HBOC extravasation. 
 Although the present study offers strong evidence to support the NO scavenging 
hypothesis, it does not investigate the interactions of HBOC with other EDRF’s.  Future 
studies can focus to elucidate the interactions of other EDRFs with HBOCs.  This study 
does offer evidence that refutes the autoregulatory response hypothesis.  Minimal 
concentrations of HBOC which do not carry significant levels of oxygen to tissues were 
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found to induce vasopressor effects in the spinotrapezius.  These results demonstrate that 
there is a different mechanism responsible for vasoconstriction at low concentrations of 
HBOC.  At higher concentrations the autoregulatory response cannot be disregarded as a 
possible contributor to vasoconstriction.  Future studies involving HBOCs with different 
P50 values at higher concentrations could further examine the role of the autoregulatory 
response in vasoconstriction. 
 In conclusion, the data presented in this study offer a means of improvement of 
current HBOCs being tested.  Further purification of the HBOCs and concomitant 
infusion with NO donors may completely abolish any hypertensive side effects, while 
maintaining the efficacy of the HBOC.  With this better understanding of the 
functionality of these HBOCs, daily clinical use of such blood substitutes may be just 
over the horizon. 
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APPENDIX 
 
 
 
  Initial ABL Values   Final ABL Values 
 pH pCO2 pO2  pH pCO2 pO2 
5.9 % Albumin Controls           
AVE 7.36 45.23 89.06  7.41 43.40 69.50
STE 0.02 2.20 3.70  0.01 1.12 3.81
HBOC 201             
AVE 7.43 39.48 88.42  7.49 29.85 77.98
STE 0.04 4.90 2.80  0.04 4.90 2.80
HBOC 205 MW 400             
AVE 7.41 39.52 90.72  7.43 36.43 74.85
STE 0.02 2.71 4.19  0.03 3.70 6.29
HBOC 205 MW 600             
AVE 7.40 40.07 80.47  7.45 31.83 77.85
STE 0.03 4.53 4.86  0.04 4.02 5.98
HBOC 201 + 
NaNO2             
AVE 7.36 48.45 81.98  7.481 30.95 82.95
STE 0.01 1.62 6.26  0.20 1.41 2.95
HBOC 205 MW 600 + NaNO2           
AVE 7.36 45.94 87.78  7.53 25.40 89.30
STE 0.02 2.35 7.39  0.02 0.77 2.32
NaNO2               
AVE 7.41 40.83 85.90  7.41 38.50 71.53
STE 0.03 2.14 3.32  0.02 2.20 4.60
L-NAME + NaNO2             
AVE 7.36 48.00 81.80  7.41 39.65 72.50
STE         0.02         1.40         4.50            0.06           9.95       3.30
                
 
 
 
Appendix I. Initial and final ABL values. 
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